Patents by Inventor Leslie Lugene Williams

Leslie Lugene Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220281963
    Abstract: Provided are methods for treating Alzheimer's disease in a human subject in need thereof when the subject develops an Amyloid Related Imaging Abnormality (ARIA) during a treatment regimen comprising administration of multiple doses of an anti-beta-amyloid antibody (e.g., BIIB037) to the subject.
    Type: Application
    Filed: February 25, 2022
    Publication date: September 8, 2022
    Inventors: Brendon Phillip Boot, Jeffrey Joseph Sevigny, Leslie Lugene Williams
  • Patent number: 10842871
    Abstract: A method for treatment of a human patient for Alzheimer's disease (AD) comprises sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody to the patient. In preferred embodiments, the antibody is administered in increasing amounts over a period of time. In preferred embodiments, the susceptibility of the patient to amyloid related imaging abnormalities (ARIA) is thereby reduced.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: November 24, 2020
    Assignee: Biogen International Neuroscience GmbH
    Inventors: James L. Ferrero, Leslie Lugene Williams, Jeffrey Joseph Sevigny
  • Publication number: 20200308259
    Abstract: Provided are methods for treating Alzheimer's disease in a human subject in need thereof when the subject develops an Amyloid Related Imaging Abnormality (ARIA) during a treatment regimen comprising administration of multiple doses of an anti-beta-amyloid antibody (e.g., BIIB037) to the subject.
    Type: Application
    Filed: June 6, 2017
    Publication date: October 1, 2020
    Inventors: Brendon Phillip Boot, Jeffrey Joseph Sevigny, Leslie Lugene Williams
  • Publication number: 20180333487
    Abstract: A method for treatment of a human patient for Alzheimer's disease (AD) comprises sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody to the patient. In preferred embodiments, the antibody is administered in increasing amounts over a period of time. In preferred embodiments, the susceptibility of the patient to amyloid related imaging abnormalities (ARIA) is thereby reduced.
    Type: Application
    Filed: December 2, 2015
    Publication date: November 22, 2018
    Inventors: James L. Ferrero, Leslie Lugene Williams, Jeffrey Joseph Sevigny